Compressing drug development timelines in oncology using phase '0' trials. (Q53208031)

12 May 2018

review article

1 reference

title

Compressing drug development timelines in oncology using phase '0' trials. (English)

1 reference

12 May 2018

1 reference

Shivaani Kummar

1

1 reference

12 May 2018

Robert Kinders

2

1 reference

12 May 2018

Larry Rubinstein

3

1 reference

12 May 2018

Ralph E Parchment

4

1 reference

12 May 2018

Anthony J Murgo

5

1 reference

12 May 2018

Jerry Collins

6

1 reference

12 May 2018

Oxana Pickeral

7

1 reference

12 May 2018

Jennifer Low

8

1 reference

12 May 2018

Seth M Steinberg

9

1 reference

12 May 2018

Martin Gutierrez

10

1 reference

12 May 2018

Sherry Yang

11

1 reference

12 May 2018

Lee Helman

12

1 reference

12 May 2018

Robert Wiltrout

13

1 reference

12 May 2018

Joseph E Tomaszewski

14

1 reference

12 May 2018

James H Doroshow

15

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 February 2007

1 reference

12 May 2018

published in

Nature Reviews Cancer

1 reference

12 May 2018

volume

7

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

131-139

1 reference

12 May 2018

Can the pharmaceutical industry reduce attrition rates?

cites work

1 reference

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

31 March 2020

1 reference

Concordance of the toxicity of pharmaceuticals in humans and in animals

31 March 2020

1 reference

Clinical trial design for target-based therapy

31 March 2020

1 reference

Rethinking clinical trials for cytostatic drugs

31 March 2020

1 reference

Improving the evaluation of new cancer treatments: challenges and opportunities

31 March 2020

1 reference

Drug development in oncology: classical cytotoxics and molecularly targeted agents

31 March 2020

1 reference

Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies

31 March 2020

1 reference

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

31 March 2020

1 reference

Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy

31 March 2020

1 reference

Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms

31 March 2020

1 reference

Matrix metalloproteinase inhibitors: how can we optimize their development?

31 March 2020

1 reference

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

31 March 2020

1 reference

Receptor imaging in oncology by means of nuclear medicine: current status

31 March 2020

1 reference

Imaging the pharmacokinetics of [F-18]FAU in patients with tumors: PET studies

31 March 2020

1 reference

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

31 March 2020

1 reference

Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?

31 March 2020

1 reference

Pharmacologically guided phase I clinical trials based upon preclinical drug development

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2066

1 reference

12 May 2018

1 reference

12 May 2018